2,6-Bis-hydroxymethyl-tetrahydro-pyran-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,6-Bis-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
• 英文别名: 2,6-bis(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₇H₁₄O₆
• 分子量: 194.18
• InChiKey: UBWUHZBLCOLWME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• COMPOUND HAVING TUMOR-RESIDENT PROPERTY
  申请人：OHTA Keisuke

  公开号：US20100202971A1

  公开（公告）日：2010-08-12

  The problem to be solved of the present invention is to provide a novel compound which specifically resides in a tumor, a method for allowing it to reside in a tumor, and a method for detecting, diagnosing, and treating tumor with use thereof. Means for solving the problem is a compound represented by chemical formula (I) wherein R is an anionic group binding to hydrogen, R 1 is OH, OCOH, OCO(CH 2 ) h CH 3 , or an acting group, h being an integer of 0 or more, R 2 is H, OH, OCOH, OCO(CH 2 ) i CH 3 , or an acting group, i being an integer of 0 or more, R 3 is OH, SO 3 H, or an acting group, R 4 is OH, SO 3 H, or an acting group, and R 5 is OH, SO 3 H, or an acting group, at least one of R 1 , R 2 , R 3 , R 4 , and R 5 containing an acting group, or pharmaceutically acceptable salts thereof.

  本发明要解决的问题是提供一种新型化合物，该化合物专门存在于肿瘤中，以及使其存在于肿瘤中的方法和使用其进行肿瘤检测、诊断和治疗的方法。解决问题的方法是提供一种由化学式（I）表示的化合物，其中R是与氢结合的负离子基团，R1是OH、OCOH、OCO（CH2）hCH3或作用基团，h是0或更多的整数，R2是H、OH、OCOH、OCO（ ）iCH3或作用基团，i是0或更多的整数，R3是OH、SO3H或作用基团，R4是OH、SO3H或作用基团，R5是OH、SO3H或作用基团，其中R1、R2、R3、R4和R5中至少有一个含有作用基团，或其药学上可接受的盐。
• Solid pharmaceutical dosage form suitable for use as drinking water medication
  申请人：Universiteit Gent

  公开号：US10335371B2

  公开（公告）日：2019-07-02

  The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.

  本发明涉及适用于饮用水药物的固体药物剂型。更具体地说，本发明提供了固体药物剂型，包括一种药物活性剂、一种亲水亲油平衡（HLB）至少为 8 的非离子表面活性剂和一种麦芽糊精。本发明还提供了此类药物剂型在兽药中的用途，尤其是作为饮用水药物；以及制备此类药物剂型的方法。
• GLUCOSYL STEVIA COMPOSITION
  申请人：PureCircle Sdn Bhd

  公开号：US20170035086A1

  公开（公告）日：2017-02-09

  Glucosyl Stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The compositions mainly comprise glucosyl derivatives with superior taste characteristics and can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
• Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same
  申请人：Tseti Ioulia

  公开号：US20170232040A1

  公开（公告）日：2017-08-17

  The present invention generally relates to iron (III) carbohydrate complexes and to processes for the manufacture thereof. The product obtainable according to the method of the present invention may be safely used to the general population or animals in the therapy of iron deficiency. The process of the invention includes the steps of (i) providing an aqueous solution of glucose syrup having a certain dextrose equivalent (DE), (ii) adding one or more oxidizing bleaching agents, thereby obtaining the activated glucose syrup; (iii) converting said activated glucose syrup into a complex with iron (III) hydroxide; and (iv) obtaining a complex of iron (III) hydroxide and activated glucose syrup.
• SOLID PHARMACEUTICAL DOSAGE FORM SUITABLE FOR USE AS DRINKING WATER MEDICATION
  申请人：Universiteit Gent

  公开号：US20180064650A1

  公开（公告）日：2018-03-08

  The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.